Product Information
ATOVAQUONE-PROGUANIL 62.5-25 is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.9275 per EA under NDC 68462040201. Its NADAC has been published 421 times since Oct 21, 2015.
FDA first approved this application on Jan 12, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
62.5; 25 mg/1; mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462040201
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATOVAQUONE; PROGUANIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091211FDA Approved
1/12/2011
TE Code
AB
On Market Since
4/8/2015
Pharmacological Classes
Price Statistics
The NADAC for ATOVAQUONE-PROGUANIL 62.5-25 has been published 421 times since Oct 21, 2015, and over the history we have for it it has declined 48.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9275 per EA |
|---|---|
| All-time high | $1.7844 (Feb 10, 2016) |
| All-time low | $0.6264 (Sep 21, 2022) |
| 52-week high | $1.3157 |
| 52-week low | $0.9275 |
| Median price | $1.2917 |
| Average price | $1.3136 |
| Largest weekly change | -62.2% (Sep 21, 2022) |
| Weeks tracked | 421 |
| Tracking since | Oct 21, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Atovaquone and Proguanil Hydrochloride Pediatric market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atovaquone and Proguanil Hydrochloride Pediatric market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimalarial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATOVAQUONE-PROGUANIL 62.5-25?
The current National Average Drug Acquisition Cost (NADAC) for ATOVAQUONE-PROGUANIL 62.5-25, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.9275 per EA (NDC 68462040201), effective Sep 30, 2026.
How has the price of ATOVAQUONE-PROGUANIL 62.5-25 changed over time?
Over the history we have for it, the NADAC for ATOVAQUONE-PROGUANIL 62.5-25 has declined 48.0%. It has been tracked across 421 weekly CMS publications since Oct 21, 2015.
What are the highest and lowest recorded NADAC prices for ATOVAQUONE-PROGUANIL 62.5-25?
Since Oct 21, 2015, the NADAC for ATOVAQUONE-PROGUANIL 62.5-25 has ranged from a low of $0.6264 (Sep 21, 2022) to a high of $1.7844 (Feb 10, 2016), with a median of $1.2917 per EA.
Are there cheaper alternatives to ATOVAQUONE-PROGUANIL 62.5-25?
No other NADAC-published product currently shares the active ingredient and strength of ATOVAQUONE-PROGUANIL 62.5-25 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ATOVAQUONE-PROGUANIL 62.5-25?
ATOVAQUONE-PROGUANIL 62.5-25 (NDC 68462040201) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.